One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States
CHU de Montpellier Hôpital Gui de Chauliac, Montpellier, France
CHU de Reims, Reims, France
CHU de Toulouse, Toulouse, France
Teradan Clinical Trials, Brandon, Florida, United States
PharmaDev Clinical Research Institute, LLC, Miami, Florida, United States
Intrepid Research, LLC, Cincinnati, Ohio, United States
Critical Care Medicine Department - Cairo University Hospitals., Cairo, Egypt
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Department of Cardiology and Vascular Medicine, Universitas Diponegoro, Kariadi Central General Hospital, Semarang, Central Java, Indonesia
Kariadi Central General Hospital, Semarang, Central Java, Indonesia
National Heart Institute, Giza, GZ, Egypt
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.